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Long-term treatment with
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We have previously demonstrated that in non-squamous
non-small cell lung cancer (nsNSCLC) cells expressing
relatively high levels of the glucocorticoid receptor (GR),
dexamethasone (Dex) induces reversible G1 arrest that
is virtually complete by 72h of Dex treatment. We have
also shown that this effect of Dex protects the cells from
the cytotoxicity of pemetrexed, a mainstay chemo-
therapy in advanced nsNSCLC that entails co-adminis-
tration of Dex. Further, induction of G1 arrest by Dex
was conﬁrmed by FLT-PET imaging of tumor lesions in
patients treated with Dex for 24h. Here we report the
effects of long-term treatment of nsNSCLC cells with Dex.
The nsNSCLC cell line models included A549 (GRhi),
H292 (GRhi), H1650 (GRlo) and H1299 (GRlo) cells as
well as clonal recombinant H1299 cells overexpressing
GR. In only the GRhi cells, Dex caused an increase in p21
peaking on Day 7 and declining by Day 14. The cells
retained proliferation potential on Day 3 as measured by
colony formation. By Day 7 of Dex treatment, the GRhi
cells but not the GRlo cells exhibited a senescence
phenotype, marked by cytosolic beta-galactosidase ac-
tivity and increases in p16 and p15 at the mRNA and
protein levels as well as signiﬁcant increases in cell size.
The GRhi cells displayed a progressively decreasing
ability to form colonies until 6 weeks of Dex treatment.
The extent of this loss of proliferation potential
was related to relative GR expression levels among the
Dex-sensitive cells. When mice bearing xenografts of
H1299 (GRlo) or isogenic recombinant H1299-GR (GRhi)
cells were implanted with slow release Dex pellets, tu-
mor growth was inhibited only in the H1299-GR cells.
Evaluation of a tissue microarray as well as a cDNA array
from clinical nsNSCLC tumors showed that about 20
percent of the tumors showed uniform expression of GRthat were comparable to the levels required for Dex to
induce senescence in vitro or to inhibit tumor growth in
vivo. The results suggest that long-term administration
of Dex could serve as an additional treatment option for
a small cohort of lung adenocarcinoma patients that
harbor uniform high levels of GR in their tumor lesions.
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Background: X-396 is a novel, potent anaplastic lym-
phoma kinase (ALK) small molecule tyrosine kinase in-
hibitor (TKI) with additional activity against MET, ABL,
Axl, EPHA2, LTK, ROS1 and SLK. It has demonstrated
signiﬁcant anti-tumor activity in both ALK TKI-naive and
crizotinib-resistant models of ALK fusion-positive NSCLC.
Methods: In this multicenter phase I/II study, patients
(pts) with advanced solid tumors were enrolled in the
phase I dose escalation portion of the study and given
X-396 on a continuous 28-day schedule (NCT01625234).
Doses from 25 up to 250 mg once daily were evaluated
and 225 mg was selected for further evaluation in the
phase II expansion. Patients in this phase were required
to have ALKþ NSCLC and measurable disease. Cohorts
included pts who were 1) ALK TKI-naïve, 2) pts who
progressed on prior crizotinib and had not received a 2nd
generation ALK TKI, 3) pts who progressed on a 2nd
generation ALK TKI (may also have received crizotinib),
4) pts with central nervous system (CNS) metastases, and
5) pts with leptomeningeal disease. All pts were assessed
for adverse events (AEs) using CTCAE version 4.03,
response to therapy was assessed using RECIST 1.1.
Results: As of the October 15, 2015 data cutoff, 53 pts
(29 men, 24 women) have been enrolled. Median age is
56 (20-79) years, the majority of patients had ECOG
performance status 1 (68%). The most common drug-
related AEs included rash (47%), nausea (28%),
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Grade (G) 1-2. The G3 treatment-related AEs were rash
(6 pts), fatigue (1 pt), decreased appetite (1 pt), dehy-
dration (1 pt), pruritus (1 pt), and face edema (1 pt). In
particular, no G3 treatment-related gastrointestinal
toxicity or liver enzyme elevation has been reported. To
date, 24 ALKþ NSCLC pts treated at doses  200 mg are
evaluable for response; partial response (PR) was
achieved in 16 pts (67%) and stable disease (SD) in 3 pts
(13%). In the crizotinib-naïve pts (n¼8), responses were
observed in 6 pts (75%) and SD in 1 pt (13%). In the 12
pts with prior crizotinib but no other ALK TKI, 10 pts
(83%) achieved PR and 1 (8%) SD. CNS responses have
been observed in both crizotinib naïve and crizotinib
resistant pts. The median duration of treatment in the 24
evaluable ALKþ pts is 23.8þ weeks, with the longest
being 112þ weeks.
Conclusion: X-396 is well-tolerated and induces re-
sponses in both crizotinib-naïve and crizotinib-resistant
ALKþ NSCLC pts, as well as patients with CNS lesions.
Enrollment is ongoing in the expansion cohorts.
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Introduction: Approximately 30% of patients with an
adenocarcinoma have a druggable driver mutation.
However, the access to tumor tissue to perform the
molecular proﬁle is often limited. Circulating tumor DNA
(ctDNA) can be used for detection and quantiﬁcation of
molecular abnormalities as a non-invasive tool. We
performed a retrospective study to assess the concor-
dance in molecular alterations between tissue biopsies
and ctDNA in 20 NSCLC patients as well as the impact of
treatment on ctDNA proﬁle.
Methods: Plasma samples were collected from 17
consecutive treatment-naïve and 3 pre-treated advanced
NSCLC patients from Gustave Roussy. For 10 patients a
second blood sample was collected 21 days after starting
chemotherapy to monitor the mutational proﬁle. DNA
was extracted from < 3 ml plasma and analyzed using
the enhanced Tam-SeqTM assay covering regions
from 35 genes. TAM-Seq data (generated using Illuminasequencing) were compared to a different NGS platform
(Ion-torrent) as well as Sanger sequencing data from
tissue biopsy samples analyzed in routine daily clinical
practice.
Results: From May 2015 to June 2015, 20 patients were
included (70% were male, 15% never-smoker, 75% had
an adenocarcinoma subtype, and 70% a stage IV). Only
40% of tumor biopsies provided sufﬁcient sample tissue
for molecular analysis. ctDNA proﬁling was possible for
all patients, which detected cancer mutations in 19 out
of 20 patients. Median number of mutations in plasma
was 2, predominantly located in KRAS, TP53 and EGFR
mutation. Half of the mutations detected in ctDNA were
observed at a frequency lower than 1%. In 10 NSCLC
patients dynamic ctDNA changes after 21 days of treat-
ment were evaluated. No new mutations were detected
at day 21. Seven out of 10 patients experienced a partial
response in CT scan by RECIST criteria. All of them had
either a lower frequency of mutations or undetectable
levels of mutations at day 21.
Conclusions: ctDNA can be used as a ‘liquid biopsy’ for
molecular proﬁling of mutations in NSCLC patients in the
absence of an invasive biopsy with a high concordance
with tissue genomic proﬁle. Also, ctDNA can potentially
be used as a surrogate marker of response. Update in 35
patients will be presented during the conference.
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Lung cancer is the leading cause of cancer-related
deaths globally. Despite advances in treatment with
targeted therapies and earlier detection, the 5-year
survival rate remains a dismal 15%. Due to the low
survival rate, there is a critical need for new therapies
targeting lung cancer. Most lung cancers have
increased activation of Wnt signaling and/or Wnt
protein expression, which makes Wnt a strong po-
tential target for the development of new lung cancer
therapeutics. Triptolide is a natural compound isolated
from the Thunder God Vine, Tripterygium wilfordii,
which has been used in traditional Chinese medicine
to treat autoimmune disorders and inﬂammation. We
previously showed that triptolide increases WIF1
expression by decreasing WIF1 promoter methylation,
thereby inhibiting the Wnt pathway. Though triptolide
